| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 36.31% | Truist Securities | $44 → $36 | Maintains | Buy |
| 11/02/2023 | 51.46% | Piper Sandler | $50 → $40 | Maintains | Overweight |
| 11/02/2023 | 21.17% | Evercore ISI Group | $36 → $32 | Downgrades | Outperform → In-Line |
| 09/22/2023 | 24.95% | Baird | $43 → $33 | Downgrades | Outperform → Neutral |
| 07/06/2023 | — | Colliers Securities | Upgrades | Neutral → Buy | |
| 02/16/2023 | 62.82% | Baird | $38 → $43 | Maintains | Outperform |
| 01/17/2023 | 81.75% | Truist Securities | $43 → $48 | Maintains | Buy |
| 01/17/2023 | 70.39% | Piper Sandler | $41 → $45 | Maintains | Overweight |
| 01/13/2023 | 66.6% | Janney Montgomery Scott | → $44 | Upgrades | Neutral → Buy |
| 10/07/2022 | 55.24% | Piper Sandler | $45 → $41 | Maintains | Overweight |
| 09/27/2022 | 62.82% | Evercore ISI Group | $45 → $43 | Maintains | Outperform |
| 07/11/2022 | 66.6% | Truist Securities | $49 → $44 | Maintains | Buy |
| 11/25/2020 | — | Evercore ISI Group | Upgrades | In-Line → Outperform | |
| 08/06/2020 | 108.25% | Piper Sandler | $38 → $55 | Maintains | Overweight |
| 06/08/2020 | 62.82% | Evercore ISI Group | → $43 | Downgrades | Outperform → In-Line |
| 05/14/2020 | 43.88% | Piper Sandler | $35 → $38 | Maintains | Overweight |
| 05/07/2020 | 51.46% | B. Riley Securities | → $40 | Downgrades | Buy → Neutral |
| 04/23/2020 | 47.67% | SunTrust Robinson Humphrey | $46 → $39 | Maintains | Buy |
| 03/20/2020 | 51.46% | B. Riley Securities | $47 → $40 | Upgrades | Neutral → Buy |
| 03/06/2020 | 77.96% | B. Riley Securities | $42 → $47 | Maintains | Neutral |
| 02/28/2020 | 96.9% | Baird | $48 → $52 | Maintains | Outperform |
| 11/18/2019 | — | Piper Sandler | Upgrades | Hold → Buy | |
| 11/07/2019 | 59.03% | B. Riley Securities | $38 → $42 | Maintains | Neutral |
| 07/10/2019 | — | Janney Montgomery Scott | Downgrades | Buy → Neutral | |
| 04/23/2019 | — | Berenberg | Initiates Coverage On | → Buy | |
| 04/10/2019 | 51.46% | Baird | → $40 | Initiates Coverage On | → Outperform |
| 03/28/2019 | 43.88% | DA Davidson | → $38 | Initiates Coverage On | → Neutral |
| 11/16/2018 | -92.43% | UBS | → $2 | Initiates Coverage On | → Sell |
| 11/12/2018 | 17.38% | B. Riley Securities | $32 → $31 | Maintains | Neutral |
What is the target price for Community Healthcare (CHCT)?
The latest price target for Community Healthcare (NYSE: CHCT) was reported by Truist Securities on November 8, 2023. The analyst firm set a price target for $36.00 expecting CHCT to rise to within 12 months (a possible 36.31% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Community Healthcare (CHCT)?
The latest analyst rating for Community Healthcare (NYSE: CHCT) was provided by Truist Securities, and Community Healthcare maintained their buy rating.
When is the next analyst rating going to be posted or updated for Community Healthcare (CHCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Community Healthcare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Community Healthcare was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
Is the Analyst Rating Community Healthcare (CHCT) correct?
While ratings are subjective and will change, the latest Community Healthcare (CHCT) rating was a maintained with a price target of $44.00 to $36.00. The current price Community Healthcare (CHCT) is trading at is $26.41, which is out of the analyst's predicted range.